Class Action,
Antitrust & Trade Reg.
Oct. 10, 2023
Gilead agrees to pay $247M to end antitrust suit over HIV drugs
U.S. District Judge Edward M. Chen of the Northern District of California scheduled a hearing for Jan. 18 to consider approval of the settlement terms.
A settlement agreement was reached in a class action that accused Gilead Sciences Inc. of engaging in anticompetitive activity that caused direct purchasers to pay too much for human immunodeficiency virus medications Truvada and Atripla, and their generic equivalents.
Under the agreement, Gilead agreed to set aside $247 million in a fund. If the trial judge approves the settlement, claims will be paid following appeals. Class counsel will...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In